An Interprofessional Team for Disease-Modifying Therapy in Alzheimer Disease Implementation
Year: 2024
Type: article
Abstract: Background: Lecanemab and other new amyloid-targeting immunotherapies for Alzheimer disease show notable promise but may also pose significant risk for patients. Recent Findings: To facilitate the implementation and monitoring of lecanemab infusions at our tertiary medical center, we convened an interprofessional team. The team created a number of resources including patient handouts and medical documentation templates as well as systems and processes that are likely to be useful to other clinical care settings and centers. Implications for Practice: It is our intent to widely share the resources and processes developed.
Source: Neurology Clinical Practice
Authors: Katherine W. Turk, Mark D. Knobel, Alexandra Nothern, Garrett Friedman, Hannah Noah, Brendan Campbell, Diana C. Anderson, Andreas Charidimou, Andrew Mills, Vanessa Coronel, Nacha Pierre, Beverly V. Reynolds, Caroline Wagner, Leanne M. Varga, John Roefaro, Laura Triantafylidis, Andrew E. Budson
Institutions: Boston University, VA Boston Healthcare System
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Award: G5616488268
OpenAlex ID: W4401632444